GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

lusvertikimab   Click here for help

GtoPdb Ligand ID: 9604

Synonyms: Effi-7 | MD-707 | OSE-127 | OSE127
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lusvertikimab (OSE-127) is a humanized monoclonal antibody that targets the alpha chain of the interleukin 7 receptor (CD127; IL7R). It antagonises IL-7R signalling by T effector cells, thus down regulating their contribution to the immune response. It was proposed to treat autoimmune diseases, transplant rejection and as an immuno-oncology candidate [2,5]. It is likely one of the candidates claimed in patent WO2015189302 [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Lusvertikimab (OSE-127) was progressed as a clinical candidate for the treatment of autoimmune conditions, principally ulcerative colitis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04882007 Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Phase 2 Interventional OSE Immunotherapeutics The CoTikiS study
NCT03980080 Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects Phase 1 Interventional OSE Immunotherapeutics 3